Loading clinical trials...
Loading clinical trials...
A Single-Arm Phase II Study With a Safety Lead-in of Magnetic Resonance-Guided Hypofractionated Adaptive Radiation Therapy With Concurrent Chemotherapy and Consolidation Durvalumab for Inoperable Stage IIB, IIIA, and Select IIIB and IIIC Non-small Cell Lung Cancer
Conditions
Interventions
ViewRay MR-Linear Accelerator
Radiation therapy
+3 more
Locations
1
United States
Washington University School of Medicine
St Louis, Missouri, United States
Start Date
June 20, 2019
Primary Completion Date
September 28, 2025
Completion Date
September 28, 2025
Last Updated
November 12, 2025
NCT01629498
NCT02495896
NCT04062708
NCT01993810
NCT02621398
NCT02186847
Lead Sponsor
Washington University School of Medicine
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions